{"created_at":"Tue Feb 11 13:52:31 +0000 2014","id":433237113459310592,"id_str":"433237113459310592","text":"@Penn's FitzGerald: #NSAIDs will confer a risk of hypertension that will relate to the degree of selectivity for COX-2\n  #NSAID #FDA $PFE","source":"web","truncated":false,"in_reply_to_status_id":null,"in_reply_to_status_id_str":null,"in_reply_to_user_id":24894213,"in_reply_to_user_id_str":"24894213","in_reply_to_screen_name":"Penn","user":{"id":593813785,"id_str":"593813785","name":"Donna Young","screen_name":"ScripDonnaDC","location":"Washington","url":"http:\/\/scripintelligence.com\/capitolcapsule\/","description":"Washington Editor for Scrip Intelligence","protected":false,"followers_count":1370,"friends_count":1584,"listed_count":60,"created_at":"Tue May 29 15:45:45 +0000 2012","favourites_count":38,"utc_offset":-18000,"time_zone":"Eastern Time (US & Canada)","geo_enabled":false,"verified":false,"statuses_count":11073,"lang":"en","contributors_enabled":false,"is_translator":false,"is_translation_enabled":false,"profile_background_color":"C0DEED","profile_background_image_url":"http:\/\/pbs.twimg.com\/profile_background_images\/828264930\/6cd70d5efa13824b51e8f8dbd73a36c3.jpeg","profile_background_image_url_https":"https:\/\/pbs.twimg.com\/profile_background_images\/828264930\/6cd70d5efa13824b51e8f8dbd73a36c3.jpeg","profile_background_tile":true,"profile_image_url":"http:\/\/pbs.twimg.com\/profile_images\/2260707079\/DonnaYoungHeadShot_normal.JPG","profile_image_url_https":"https:\/\/pbs.twimg.com\/profile_images\/2260707079\/DonnaYoungHeadShot_normal.JPG","profile_banner_url":"https:\/\/pbs.twimg.com\/profile_banners\/593813785\/1364590876","profile_link_color":"0084B4","profile_sidebar_border_color":"FFFFFF","profile_sidebar_fill_color":"DDEEF6","profile_text_color":"333333","profile_use_background_image":true,"default_profile":false,"default_profile_image":false,"following":null,"follow_request_sent":null,"notifications":null},"geo":null,"coordinates":null,"place":null,"contributors":null,"retweet_count":0,"favorite_count":0,"entities":{"hashtags":[{"text":"NSAIDs","indices":[20,27]},{"text":"NSAID","indices":[121,127]},{"text":"FDA","indices":[128,132]}],"symbols":[{"text":"PFE","indices":[133,137]}],"urls":[],"user_mentions":[{"screen_name":"Penn","name":"Penn","id":24894213,"id_str":"24894213","indices":[0,5]}]},"favorited":false,"retweeted":false,"filter_level":"medium","lang":"en"}
{"created_at":"Tue Feb 11 14:31:33 +0000 2014","id":433246936502902784,"id_str":"433246936502902784","text":"RT @SarahKarlin: UPenn's Garrett FitzGerald says $PFE's PRECISION trial evaluating safety of Celebrex v. ibuprofen v. naproxen is biased to\u2026","source":"web","truncated":false,"in_reply_to_status_id":null,"in_reply_to_status_id_str":null,"in_reply_to_user_id":null,"in_reply_to_user_id_str":null,"in_reply_to_screen_name":null,"user":{"id":44438256,"id_str":"44438256","name":"Matthew Herper","screen_name":"matthewherper","location":"New York","url":"http:\/\/blogs.forbes.com\/matthewherper","description":"Forbes reporter covering science and medicine","protected":false,"followers_count":35915,"friends_count":1461,"listed_count":1561,"created_at":"Wed Jun 03 19:45:32 +0000 2009","favourites_count":70,"utc_offset":-18000,"time_zone":"Eastern Time (US & Canada)","geo_enabled":false,"verified":true,"statuses_count":25918,"lang":"en","contributors_enabled":false,"is_translator":false,"is_translation_enabled":false,"profile_background_color":"022330","profile_background_image_url":"http:\/\/abs.twimg.com\/images\/themes\/theme15\/bg.png","profile_background_image_url_https":"https:\/\/abs.twimg.com\/images\/themes\/theme15\/bg.png","profile_background_tile":false,"profile_image_url":"http:\/\/pbs.twimg.com\/profile_images\/249031463\/herperhead_normal.jpg","profile_image_url_https":"https:\/\/pbs.twimg.com\/profile_images\/249031463\/herperhead_normal.jpg","profile_banner_url":"https:\/\/pbs.twimg.com\/profile_banners\/44438256\/1353414668","profile_link_color":"0084B4","profile_sidebar_border_color":"A8C7F7","profile_sidebar_fill_color":"C0DFEC","profile_text_color":"333333","profile_use_background_image":true,"default_profile":false,"default_profile_image":false,"following":null,"follow_request_sent":null,"notifications":null},"geo":null,"coordinates":null,"place":null,"contributors":null,"retweeted_status":{"created_at":"Tue Feb 11 14:31:02 +0000 2014","id":433246807435395073,"id_str":"433246807435395073","text":"UPenn's Garrett FitzGerald says $PFE's PRECISION trial evaluating safety of Celebrex v. ibuprofen v. naproxen is biased toward null. #NSAIDs","source":"web","truncated":false,"in_reply_to_status_id":null,"in_reply_to_status_id_str":null,"in_reply_to_user_id":null,"in_reply_to_user_id_str":null,"in_reply_to_screen_name":null,"user":{"id":42703163,"id_str":"42703163","name":"Sarah Karlin","screen_name":"SarahKarlin","location":"Washington, DC ","url":null,"description":"Pharmaceutical & Healthcare Reporter with @ThePinkSheet1. Formerly of @FDAnewsPharma, GW Alum, Inflexible Yogi, Marathon Runner. Tweets are my own.","protected":false,"followers_count":1190,"friends_count":866,"listed_count":55,"created_at":"Tue May 26 19:50:18 +0000 2009","favourites_count":171,"utc_offset":null,"time_zone":null,"geo_enabled":false,"verified":false,"statuses_count":3173,"lang":"en","contributors_enabled":false,"is_translator":false,"is_translation_enabled":false,"profile_background_color":"709397","profile_background_image_url":"http:\/\/abs.twimg.com\/images\/themes\/theme6\/bg.gif","profile_background_image_url_https":"https:\/\/abs.twimg.com\/images\/themes\/theme6\/bg.gif","profile_background_tile":false,"profile_image_url":"http:\/\/pbs.twimg.com\/profile_images\/3003251654\/fe0f117eaf6caec86b3bb3205cd924ce_normal.jpeg","profile_image_url_https":"https:\/\/pbs.twimg.com\/profile_images\/3003251654\/fe0f117eaf6caec86b3bb3205cd924ce_normal.jpeg","profile_link_color":"FF3300","profile_sidebar_border_color":"86A4A6","profile_sidebar_fill_color":"A0C5C7","profile_text_color":"333333","profile_use_background_image":true,"default_profile":false,"default_profile_image":false,"following":null,"follow_request_sent":null,"notifications":null},"geo":null,"coordinates":null,"place":null,"contributors":null,"retweet_count":1,"favorite_count":0,"entities":{"hashtags":[{"text":"NSAIDs","indices":[133,140]}],"symbols":[{"text":"PFE","indices":[32,36]}],"urls":[],"user_mentions":[]},"favorited":false,"retweeted":false,"lang":"en"},"retweet_count":0,"favorite_count":0,"entities":{"hashtags":[{"text":"NSAIDs","indices":[139,140]}],"symbols":[{"text":"PFE","indices":[49,53]}],"urls":[],"user_mentions":[{"screen_name":"SarahKarlin","name":"Sarah Karlin","id":42703163,"id_str":"42703163","indices":[3,15]}]},"favorited":false,"retweeted":false,"filter_level":"medium","lang":"en"}
{"created_at":"Tue Feb 11 19:27:52 +0000 2014","id":433321507058884609,"id_str":"433321507058884609","text":"RT @cbtadvisors: Important data coming out: @Athersys nears end Ph2 in IBD. Partnered with $PFE #BIOCEO14","source":"\u003ca href=\"http:\/\/www.hootsuite.com\" rel=\"nofollow\"\u003eHootSuite\u003c\/a\u003e","truncated":false,"in_reply_to_status_id":null,"in_reply_to_status_id_str":null,"in_reply_to_user_id":null,"in_reply_to_user_id_str":null,"in_reply_to_screen_name":null,"user":{"id":219017158,"id_str":"219017158","name":"Rob Wright","screen_name":"RfwrightLSL","location":"Erie, PA","url":"http:\/\/www.lifescienceleader.com\/jp\/editorsblog","description":"Chief Editor-Life Science Leader mag, sports fanatic & family guy. I write primarily about the bio\/pharma industry execs, leadership & business management","protected":false,"followers_count":4346,"friends_count":204,"listed_count":163,"created_at":"Tue Nov 23 18:21:54 +0000 2010","favourites_count":511,"utc_offset":-18000,"time_zone":"Eastern Time (US & Canada)","geo_enabled":true,"verified":false,"statuses_count":24651,"lang":"en","contributors_enabled":false,"is_translator":false,"is_translation_enabled":false,"profile_background_color":"9AE4E8","profile_background_image_url":"http:\/\/pbs.twimg.com\/profile_background_images\/706930846\/20dfb4089659e6b5a06916dbcbdf157d.jpeg","profile_background_image_url_https":"https:\/\/pbs.twimg.com\/profile_background_images\/706930846\/20dfb4089659e6b5a06916dbcbdf157d.jpeg","profile_background_tile":false,"profile_image_url":"http:\/\/pbs.twimg.com\/profile_images\/2828236033\/0a61845353adfa75a11145eee4d0d51f_normal.png","profile_image_url_https":"https:\/\/pbs.twimg.com\/profile_images\/2828236033\/0a61845353adfa75a11145eee4d0d51f_normal.png","profile_link_color":"0084B4","profile_sidebar_border_color":"FFFFFF","profile_sidebar_fill_color":"DDFFCC","profile_text_color":"333333","profile_use_background_image":true,"default_profile":false,"default_profile_image":false,"following":null,"follow_request_sent":null,"notifications":null},"geo":null,"coordinates":null,"place":null,"contributors":null,"retweeted_status":{"created_at":"Tue Feb 11 19:20:40 +0000 2014","id":433319695861952514,"id_str":"433319695861952514","text":"Important data coming out: @Athersys nears end Ph2 in IBD. Partnered with $PFE #BIOCEO14","source":"\u003ca href=\"https:\/\/about.twitter.com\/products\/tweetdeck\" rel=\"nofollow\"\u003eTweetDeck\u003c\/a\u003e","truncated":false,"in_reply_to_status_id":null,"in_reply_to_status_id_str":null,"in_reply_to_user_id":null,"in_reply_to_user_id_str":null,"in_reply_to_screen_name":null,"user":{"id":82095703,"id_str":"82095703","name":"Steven Dickman","screen_name":"cbtadvisors","location":"Cambridge, MA, USA","url":"http:\/\/bostonbiotechwatch.com","description":"Founder-CEO of CBT Advisors, a life sciences consultancy. Blogger. Former venture capitalist with TVM Capital, former reporter with Nature, The Economist.","protected":false,"followers_count":1857,"friends_count":924,"listed_count":68,"created_at":"Tue Oct 13 13:36:28 +0000 2009","favourites_count":1137,"utc_offset":-21600,"time_zone":"Central Time (US & Canada)","geo_enabled":false,"verified":false,"statuses_count":3716,"lang":"en","contributors_enabled":false,"is_translator":false,"is_translation_enabled":false,"profile_background_color":"C0DEED","profile_background_image_url":"http:\/\/abs.twimg.com\/images\/themes\/theme1\/bg.png","profile_background_image_url_https":"https:\/\/abs.twimg.com\/images\/themes\/theme1\/bg.png","profile_background_tile":false,"profile_image_url":"http:\/\/pbs.twimg.com\/profile_images\/983366435\/megpix-030907-209_4x6_normal.jpg","profile_image_url_https":"https:\/\/pbs.twimg.com\/profile_images\/983366435\/megpix-030907-209_4x6_normal.jpg","profile_link_color":"0084B4","profile_sidebar_border_color":"C0DEED","profile_sidebar_fill_color":"DDEEF6","profile_text_color":"333333","profile_use_background_image":true,"default_profile":true,"default_profile_image":false,"following":null,"follow_request_sent":null,"notifications":null},"geo":null,"coordinates":null,"place":null,"contributors":null,"retweet_count":1,"favorite_count":0,"entities":{"hashtags":[{"text":"BIOCEO14","indices":[79,88]}],"symbols":[{"text":"PFE","indices":[74,78]}],"urls":[],"user_mentions":[{"screen_name":"athersys","name":"Athersys Inc","id":254111345,"id_str":"254111345","indices":[27,36]}]},"favorited":false,"retweeted":false,"lang":"en"},"retweet_count":0,"favorite_count":0,"entities":{"hashtags":[{"text":"BIOCEO14","indices":[96,105]}],"symbols":[{"text":"PFE","indices":[91,95]}],"urls":[],"user_mentions":[{"screen_name":"cbtadvisors","name":"Steven Dickman","id":82095703,"id_str":"82095703","indices":[3,15]},{"screen_name":"athersys","name":"Athersys Inc","id":254111345,"id_str":"254111345","indices":[44,53]}]},"favorited":false,"retweeted":false,"filter_level":"medium","lang":"en"}
